Anika Therapeutics Company Profile (NASDAQ:ANIK)

About Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics logoAnika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company's therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company's ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: Health Care Supplies
  • Symbol: NASDAQ:ANIK
  • CUSIP: 03525510
  • Web:
  • Market Cap: $875.84 million
  • Outstanding Shares: 14,658,000
Average Prices:
  • 50 Day Moving Avg: $57.54
  • 200 Day Moving Avg: $50.30
  • 52 Week Range: $41.38 - $60.27
  • Trailing P/E Ratio: 26.57
  • Foreward P/E Ratio: 35.39
  • P/E Growth: 2.73
Sales & Book Value:
  • Annual Revenue: $111.36 million
  • Price / Sales: 7.87
  • Book Value: $16.66 per share
  • Price / Book: 3.59
  • EBITDA: $56.02 million
  • Net Margins: 30.44%
  • Return on Equity: 14.88%
  • Return on Assets: 13.78%
  • Current Ratio: 14.35%
  • Quick Ratio: 13.04%
  • Average Volume: 89,905 shs.
  • Beta: 1.66
  • Short Ratio: 14.7

Frequently Asked Questions for Anika Therapeutics (NASDAQ:ANIK)

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics Inc. (NASDAQ:ANIK) posted its earnings results on Wednesday, July, 26th. The company reported $0.76 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.44 by $0.32. The company earned $33.50 million during the quarter, compared to analysts' expectations of $27.20 million. Anika Therapeutics had a net margin of 30.44% and a return on equity of 14.88%. Anika Therapeutics's quarterly revenue was up 25.9% on a year-over-year basis. During the same period last year, the company posted $0.57 earnings per share. View Anika Therapeutics' Earnings History.

When will Anika Therapeutics make its next earnings announcement?

Anika Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Anika Therapeutics.

Who are some of Anika Therapeutics' key competitors?

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the folowing people:

  • Joseph G. Darling, President
  • Charles H. Sherwood Ph.D., Chief Executive Officer, Director
  • Sylvia Cheung, Chief Financial Officer, Treasurer, Secretary
  • Dana M. Alexander, Chief Operating Officer
  • Edward Ahn Ph.D., Chief Technology and Strategy Officer
  • Richard Hague, Chief Commercial Officer
  • Joseph Lyon Bower Ph.D., Lead Independent Director
  • Raymond J. Land, Independent Director
  • Glenn R. Larsen Ph.D., Independent Director
  • Jeffrey S. Thompson, Independent Director

Who owns Anika Therapeutics stock?

Anika Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC (11.49%), Fisher Asset Management LLC (0.72%) and Eqis Capital Management Inc. (0.28%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Jeffery S Thompson, Joseph I Bower and Raymond J Land. View Institutional Ownership Trends for Anika Therapeutics.

Who bought Anika Therapeutics stock? Who is buying Anika Therapeutics stock?

Anika Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC and Eqis Capital Management Inc.. View Insider Buying and Selling for Anika Therapeutics.

How do I buy Anika Therapeutics stock?

Shares of Anika Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anika Therapeutics' stock price today?

One share of Anika Therapeutics stock can currently be purchased for approximately $59.81.

MarketBeat Community Rating for Anika Therapeutics (NASDAQ ANIK)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  89 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  152
MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Anika Therapeutics (NASDAQ:ANIK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Anika Therapeutics (NASDAQ:ANIK)
Price Target History for Anika Therapeutics (NASDAQ:ANIK)
Analysts' Ratings History for Anika Therapeutics (NASDAQ:ANIK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/27/2016Northland SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
2/26/2016Barrington ResearchBoost Price TargetOutperform$45.00 -> $49.00N/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Anika Therapeutics (NASDAQ:ANIK)
Earnings by Quarter for Anika Therapeutics (NASDAQ:ANIK)
Earnings History by Quarter for Anika Therapeutics (NASDAQ ANIK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017$0.44N/AView Earnings Details
7/26/2017Q2 2017$0.44$0.76$27.20 million$33.50 millionViewN/AView Earnings Details
5/3/2017Q1 2017$0.38$0.37$23.89 million$23.39 millionViewListenView Earnings Details
2/15/2017Q416$0.53$0.54$27.84 million$28.70 millionViewN/AView Earnings Details
10/26/2016Q316$0.47$0.59$26.60 million$25.79 millionViewListenView Earnings Details
7/27/2016Q216$0.44$0.57$24.75 million$26.60 millionViewListenView Earnings Details
4/27/2016Q116$0.28$0.45$19.26 million$22.30 millionViewListenView Earnings Details
2/24/2016Q415$0.60$0.72$28.19 million$25.60 millionViewListenView Earnings Details
10/28/2015Q315$0.34$0.55$22.36 million$23.70 millionViewListenView Earnings Details
7/29/2015Q215$0.34$0.51$21.65 million$22.90 millionViewListenView Earnings Details
4/28/2015Q115$0.21$0.23$16.20 million$15.50 millionViewListenView Earnings Details
2/25/2015Q414$0.48$0.51$24.60 million$23.30 millionViewListenView Earnings Details
10/29/2014Q314$0.33$0.40$20.33 million$22.10 millionViewListenView Earnings Details
7/30/2014Q214$0.57$0.60$28.20 million$26.27 millionViewListenView Earnings Details
4/29/2014Q114$0.25$0.97$16.03 million$34.00 millionViewN/AView Earnings Details
2/26/2014Q413$0.42$0.44$21.91 million$21.30 millionViewListenView Earnings Details
10/31/2013Q313$0.14$0.33$16.96 million$17.80 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.25$0.40$17.09 million$20.80 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Anika Therapeutics (NASDAQ:ANIK)
2017 EPS Consensus Estimate: $1.85
2018 EPS Consensus Estimate: $1.75
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.34$0.42$0.38
Q2 20172$0.42$0.47$0.45
Q3 20172$0.39$0.42$0.41
Q4 20172$0.62$0.62$0.62
Q1 20182$0.32$0.36$0.34
Q2 20181$0.47$0.47$0.47
Q3 20181$0.44$0.44$0.44
Q4 20181$0.50$0.50$0.50
(Data provided by Zacks Investment Research)


Dividend History for Anika Therapeutics (NASDAQ:ANIK)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Anika Therapeutics (NASDAQ:ANIK)
Insider Ownership Percentage: 6.57%
Institutional Ownership Percentage: 84.32%
Insider Trades by Quarter for Anika Therapeutics (NASDAQ:ANIK)
Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)
Insider Trades by Quarter for Anika Therapeutics (NASDAQ:ANIK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/16/2017Charles H SherwoodCEOSell3,293$60.04$197,711.72View SEC Filing  
10/13/2017Charles H SherwoodCEOSell7,124$60.08$428,009.92View SEC Filing  
7/27/2017Charles H SherwoodCEOSell63,799$50.79$3,240,351.21View SEC Filing  
7/5/2017Charles H SherwoodCEOSell14,201$50.03$710,476.03View SEC Filing  
5/22/2017Jeffery S ThompsonDirectorSell10,725$47.39$508,257.75View SEC Filing  
11/9/2016Joseph I BowerDirectorSell540$43.39$23,430.60View SEC Filing  
2/25/2016Raymond J LandDirectorSell2,695$43.62$117,555.90View SEC Filing  
2/27/2015Raymond J LandDirectorSell4,621$39.49$182,483.29View SEC Filing  
5/1/2014Charles H SherwoodCEOSell83,780$44.32$3,713,129.60View SEC Filing  
2/28/2014Charles H SherwoodCEOSell200,000$41.70$8,340,000.00View SEC Filing  
8/22/2013John C MoranDirectorSell5,000$24.35$121,750.00View SEC Filing  
8/8/2013Steve E WheelerDirectorSell26,984$23.61$637,092.24View SEC Filing  
8/7/2013Steve E WheelerDirectorSell11,016$27.01$297,542.16View SEC Filing  
8/6/2013Farmaceutici S.P.A. FidiaMajor ShareholderSell1,270,000$24.52$31,140,400.00View SEC Filing  
7/15/2013Charles H SherwoodCEOSell75,000$20.11$1,508,250.00View SEC Filing  
7/9/2013Charles H SherwoodCEOSell49,185$18.06$888,281.10View SEC Filing  
7/5/2013Charles H SherwoodCEOSell34,662$18.01$624,262.62View SEC Filing  
6/19/2013Charles H SherwoodCEOSell1,847$18.00$33,246.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Anika Therapeutics (NASDAQ:ANIK)
Latest Headlines for Anika Therapeutics (NASDAQ:ANIK)
DateHeadline logoInsider Selling: Anika Therapeutics Inc. (ANIK) CEO Sells 3,293 Shares of Stock - October 18 at 8:10 PM logoETFs with exposure to Anika Therapeutics, Inc. : October 18, 2017 - October 18 at 5:09 PM logoAnika Therapeutics Inc. (ANIK) to Release Quarterly Earnings on Wednesday - October 18 at 2:16 AM logoANIK Expands Horizons, FENC Hits Study Goals, IMDZ Abuzz, One More For Opdivo - October 17 at 4:46 PM logoAnika Therapeutics (ANIK) Reports Regulatory Approval for MONOVISC in Australia - October 17 at 4:46 PM logoInsider Selling: Anika Therapeutics Inc. (ANIK) CEO Sells 7,124 Shares of Stock - October 16 at 7:40 PM logoAnika Announces Regulatory Approval for MONOVISC® in Australia for the Treatment of Pain Associated with Osteoarthritis of all Synovial Joints - October 16 at 4:44 PM logoAnika to Issue Third-Quarter 2017 Financial Results and Business Highlights on Wednesday, October 25 - October 11 at 5:26 PM logo Anika Therapeutics Inc. (ANIK) Given $53.00 Consensus Price Target by Brokerages - October 9 at 2:26 AM logoAnalyzing Anika Therapeutics (ANIK) & Its Peers - October 3 at 6:20 PM logoViscosupplementation Market By Product, By Region And Segment Forecasts, 2014 - 2025 - September 22 at 1:37 PM logoHead-To-Head Survey: Anika Therapeutics (ANIK) versus Its Peers - September 16 at 6:30 PM logoViscosupplementation Market Worth $6.52 Billion by 2025: Grand View Research, Inc. - September 4 at 4:25 PM logoAnika Announces Appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs - August 28 at 9:02 PM logoAnalyzing Anika Therapeutics (ANIK) and Syros Pharmaceuticals (SYRS) - August 26 at 12:22 AM logoAnika (ANIK) Grows in Orthopedic Medicines on Positive Data - August 15 at 4:52 PM logoETFs with exposure to Anika Therapeutics, Inc. : August 15, 2017 - August 15 at 4:52 PM logoAnika Announces Publication of Data Demonstrating the Efficacy and Safety of HYALOFAST® in Combination with Stem Cells for the Treatment of Cartilage Lesions on the Knee - August 7 at 4:46 PM logoNine Chapters Capital Management LLC Buys Pattern Energy Group Inc, Constellation Brands Inc, ... - August 1 at 9:52 PM logoAnika Therapeutics, Inc. :ANIK-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017 - August 1 at 4:51 PM logoInsider Selling: Anika Therapeutics Inc. (NASDAQ:ANIK) CEO Sells 63,799 Shares of Stock - July 31 at 7:29 PM logoHead to Head Contrast: Tokai Pharmaceuticals (NVUS) and Anika Therapeutics (ANIK) - July 28 at 12:33 PM logoGainers & Losers Of July 27: CAPR, ANIK, MMSI, AZN, TTPH, AGEN... - July 28 at 1:43 AM logoEdited Transcript of ANIK earnings conference call or presentation 27-Jul-17 1:00pm GMT - July 28 at 1:43 AM logoAnika Announces Appointment of Joseph Darling as President - July 27 at 3:35 PM logoAnika Therapeutics Inc. (NASDAQ:ANIK) Issues Earnings Results - July 27 at 12:39 PM logoAnika posts 2Q profit - July 26 at 9:28 PM logoAnika Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ANIK-US : July 26, 2017 - July 26 at 4:27 PM logoAnika Reports Strong Second Quarter 2017 Financial Results - July 26 at 4:27 PM logoAnika Announces Regulatory Approval for MONOVISC® in India for the Treatment of Pain Associated with Osteoarthritis of All Synovial Joints - July 24 at 6:15 PM logoCritical Analysis: Anika Therapeutics (NASDAQ:ANIK) & KalVista Pharmaceuticals (KALV) - July 24 at 4:06 PM logoAnika Therapeutics Inc. (ANIK) Set to Announce Earnings on Tuesday - July 18 at 8:16 AM logoBRIEF-Anika announces $5 mln milestone payment from U.S. commercial sales of Monovisc - July 17 at 9:19 PM logoAnika Announces $5 Million Milestone Payment from U.S. Commercial Sales of MONOVISC - July 17 at 4:16 PM logoAnika pays former medical chief $350K to thwart possible lawsuit - July 17 at 12:36 PM logoAnika Therapeutics (ANIK) Presents At Singular Summer Solstice Conference - Slideshow - July 13 at 4:39 PM logoAnika Therapeutics, Inc. – Value Analysis (NASDAQ:ANIK) : July 12, 2017 - July 12 at 4:24 PM logoAnika to Issue Second-Quarter 2017 Financial Results and Business Highlights on Wednesday, July 26 - July 12 at 4:24 PM logoAnika Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ANIK-US : July 11, 2017 - July 11 at 5:08 PM logoNew Strong Sell Stocks for July 11th - July 11 at 5:07 PM logoETFs with exposure to Anika Therapeutics, Inc. : July 11, 2017 - July 11 at 5:07 PM logoResearch Analysts Offer Predictions for Anika Therapeutics Inc.'s Q2 2017 Earnings (ANIK) - July 10 at 7:36 AM logoCharles H. Sherwood Sells 14,201 Shares of Anika Therapeutics Inc. (NASDAQ:ANIK) Stock - July 6 at 7:22 PM logoAnika to Present at the Singular Research Summer Solstice Conference on July 13, 2017 - July 6 at 5:10 PM logoFacial Injectables Market to Reach $17.2 Billion by 2025 - Fueled by Advancements in Facial Rejuvenation Procedures - Research and Markets - June 24 at 2:12 AM logoFacial Injectables Market is expected to reach USD 17.2 billion by 2025 - June 20 at 9:09 PM logoFacial Injectables Market Size Worth $17.2 Billion By 2025: Grand View Research, Inc. - June 13 at 1:04 PM logoAnika Therapeutics Inc. 2017 Q1 - Results - Earnings Call Slides - May 7 at 11:29 AM logoGlobal Hyaluranoic Acid Raw Material Market expected to be worth 7.25 Billion USD by 2024 - May 3 at 9:31 AM logo6 Companies That Offer Strong Value Potential for 2nd-Quarter 2017 - Nasdaq - March 31 at 8:45 PM



Anika Therapeutics (ANIK) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.